



SOLVE
ON.

2025 Incyte Ingenuity Awards in GVHD™ Awarded to The Ohio State University (OSU) Comprehensive Cancer Center and Circadian OS

Wilmington, Del. – November 7, 2025 – Incyte is proud to announce that The Ohio State University (OSU) Comprehensive Cancer Center and Circadian OS, in partnership with Mount Sinai’s Light and Health Research Center, have been selected as the recipients of the 2025 Incyte Ingenuity Awards in GVHD™. This annual award program celebrates and supports two innovative projects designed to meet the specific needs of individuals impacted by graft-versus-host disease (GVHD), including patients, caregivers and healthcare providers.

"It is our honor to award The Ohio State University Comprehensive Cancer Center and Circadian OS the 2025 Incyte Ingenuity Awards in GVHD. Their projects provide new approaches to address overlooked needs of people living with GVHD, including its emotional toll and the challenges associated with managing lesser-known symptoms," said Mohamed Issa, Executive Vice President and Head of U.S. Oncology, Incyte. "GVHD is a devastating disease, and these projects offer community-generated solutions that will have a positive impact on patient care."

Through its project, *Identifying Genitourinary GVHD Diagnostic and Prognostic Qualitative Factors*, the OSU Comprehensive Cancer Center aims to address the current limitations of clinical care management of genitourinary (GU) GVHD, an under-recognized manifestation of chronic GVHD. In collaboration with OSU’s James Oncology Rehabilitation, the project will pilot the development of a questionnaire for screening and longitudinal symptom assessments of post-transplant patients.

Circadian OS, in collaboration with Mount Sinai’s Light and Health Research Center, plans to develop *RhythmCare: A Personalized Circadian Wellness Program for GVHD Patients* – the first circadian-aligned support tool tailored to patients with GVHD. The tablet-based educational toolkit will teach the benefits of and how to utilize light exposure, structured routines and circadian principles to enhance physical wellbeing in those with GVHD. Resources will include support guides and personalized daily schedules, both revolving around circadian light exposure to help ameliorate symptoms.

Applications for the 2025 Incyte Ingenuity Awards in GVHD were evaluated by an independent judging panel consisting of five GVHD community experts and advocates, including: Marti Cowden, Executive Vice President, Meredith A Cowden Foundation; Christina Ferraro, CNP, Outpatient Advanced Practice Provider Manager, Director of Survivorship and nurse practitioner, Transplantation and Cellular Therapy and Apheresis, Cleveland Clinic Cancer Institute; Pooja Khandelwal, M.D., Member, Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Associate Professor, UC Department of Pediatrics; Catherine Lee, M.D., Associate Professor, Clinical Research Division, Fred Hutchinson Cancer Center, Associate Professor,

Division of Hematology and Oncology, University of Washington School of Medicine; Susan Stewart, Founder and Executive Director, Blood and Marrow Transplant Information Network. To maintain the integrity of the judging process, any judge affiliated with an applying organization was precluded from the review of that organization's application.

To read more about these winning initiatives, and for more information about the Incyte Ingenuity Awards in GVHD, visit <https://www.incyteingenuityawards.com/gvhd/>.

About GVHD

Graft-versus-host disease (GVHD) is a condition that can occur after an allogeneic stem cell transplant (the transfer of stem cells from a donor) where the donated cells initiate an immune response and attack the transplant recipient's organs, leading to significant morbidity and mortality. There are two major forms of GVHD, acute and chronic, that can affect multiple organ systems including the skin, gastrointestinal (digestive) tract, lung and liver.¹

About Incyte

A global biopharmaceutical company on a mission to *Solve On*, Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For additional information on Incyte, please visit incyte.com or follow us on social media: [LinkedIn](#), [X](#), [Instagram](#), [Facebook](#), [YouTube](#).

###

Contacts:

Media

media@incyte.com

Investors

ir@incyte.com

¹ Ferrara JL., et al. Graft-versus-host disease. Lancet. 2009;373(9674):1550-1561.